Encouraging Interim Data From Early-Stage COVID-19 Study With Cell Therapy Lifts Agenus Shares

by Vandana Singh, Benzinga Editor

February 4, 2021 10:47 AM | 1 min read

Agenus Inc (NASDAQ: AGEN) has announced positive preliminary results from its Phase 1 trial evaluating its iNKT cell therapy in patients with moderate to severe symptoms of COVID-19 through its subsidiary, AgenTus Therapeutics.
Preliminary data show that three out of the four patients dosed to date were extubated and released after treatment. Notably, two of these patients were extubated within 24 hours of dosing.
AgenTus is accruing and treating patients with dose escalation underway.
Dose escalation is expected to complete in the first half of this year for an initiation into a Phase 2 trial with data readouts expected in the fourth quarter of this year.
Price Action: AGEN gained 6.14% at $4.67 on the last check Thursday.

Posted In: Biotech News Penny Stocks Small Cap Top Stories General Covid-19 Phase 1 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.